uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
IL-22 Binding Protein Promotes the Disease Process in Multiple Sclerosis
Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Neuroimmunol Unit, S-17177 Stockholm, Sweden.
Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Neuroimmunol Unit, S-17177 Stockholm, Sweden.
Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Neuroimmunol Unit, S-17177 Stockholm, Sweden.
Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Neuroimmunol Unit, S-17177 Stockholm, Sweden.
Show others and affiliations
2019 (English)In: Journal of Immunology, ISSN 0022-1767, E-ISSN 1550-6606, Vol. 203, no 4, p. 888-898Article in journal (Refereed) Published
Abstract [en]

Genome-wide association studies have mapped the specific sequence variants that predispose for multiple sclerosis (MS). The pathogenic mechanisms that underlie these associations could be leveraged to develop safer and more effective MS treatments but are still poorly understood. In this article, we study the genetic risk variant rs17066096 and the candidate gene that encodes IL-22 binding protein (IL-22BP), an antagonist molecule of the cytokine IL-22. We show that monocytes from carriers of the risk genotype of rs17066096 express more IL-22BP in vitro and cerebrospinal fluid levels of IL-22BP correlate with MS lesion load on magnetic resonance imaging. We confirm the pathogenicity of IL-22BP in both rat and mouse models of MS and go on to suggest a pathogenic mechanism involving lack of IL-22-mediated inhibition of T cell-derived IFN-gamma expression. Our results demonstrate a pathogenic role of IL-22BP in three species with a potential mechanism of action involving T cell polarization, suggesting a therapeutic potential of IL-22 in the context of MS.

Place, publisher, year, edition, pages
AMER ASSOC IMMUNOLOGISTS , 2019. Vol. 203, no 4, p. 888-898
National Category
Immunology in the medical area Immunology
Identifiers
URN: urn:nbn:se:uu:diva-393331DOI: 10.4049/jimmunol.1900400ISI: 000478980700015PubMedID: 31292217OAI: oai:DiVA.org:uu-393331DiVA, id: diva2:1355357
Funder
Swedish Research Council, D0283001Knut and Alice Wallenberg Foundation, 2011.0073AstraZenecaAvailable from: 2019-09-27 Created: 2019-09-27 Last updated: 2019-09-27Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Tandre, KarolinaRönnblom, Lars

Search in DiVA

By author/editor
Tandre, KarolinaRönnblom, Lars
By organisation
RheumatologyScience for Life Laboratory, SciLifeLab
In the same journal
Journal of Immunology
Immunology in the medical areaImmunology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 3 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf